- Open
- 0.13
- High
- 0.14
- Low
- 0.12
- Close
- 0.14
- Change
- -0.01 (-7.69%)
- Volume
- 16,487,617
| 13 Aug 2026 | 07:00:05 | Partnership with Dubai London Clinics & Hospitals |
| 10 Aug 2026 | 14:00:00 | Fundraising, Posting of Circular & Notice of GM |
| 28 Jul 2026 | 07:00:06 | First commercial agreement for EpiSwitch® Orion |
| 17 Jul 2026 | 13:15:00 | Holding(s) in Company |
| 7 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 14 Mar 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 28 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Oxford Biodynamics plc develops and commercializes precision medicine tests based on its proprietary EpiSwitch® 3D gene regulation technology. The company offers a range of molecular diagnostic tests, including the EpiSwitch® Prostate Screening Test and the EpiSwitch® Checkpoint Inhibitor Response Test, which assist healthcare providers in making informed treatment decisions. Oxford Biodynamics collaborates with pharmaceutical, biotech, and academic institutions for clinical development and biomarker discovery, operating primarily in the UK and the US, with additional facilities in Malaysia. The company also plans to launch the EpiSwitch® Orion cloud platform to enhance genomic data analysis and accessibility.
| 13 Aug 2026 | 07:00:05 | Partnership with Dubai London Clinics & Hospitals |
| 10 Aug 2026 | 14:00:00 | Fundraising, Posting of Circular & Notice of GM |
| 28 Jul 2026 | 07:00:06 | First commercial agreement for EpiSwitch® Orion |
| 17 Jul 2026 | 13:15:00 | Holding(s) in Company |
| 7 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 14 Mar 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 28 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Oxford Biodynamics plc develops and commercializes precision medicine tests based on its proprietary EpiSwitch® 3D gene regulation technology. The company offers a range of molecular diagnostic tests, including the EpiSwitch® Prostate Screening Test and the EpiSwitch® Checkpoint Inhibitor Response Test, which assist healthcare providers in making informed treatment decisions. Oxford Biodynamics collaborates with pharmaceutical, biotech, and academic institutions for clinical development and biomarker discovery, operating primarily in the UK and the US, with additional facilities in Malaysia. The company also plans to launch the EpiSwitch® Orion cloud platform to enhance genomic data analysis and accessibility.
| 17 Jul 2026 | 09:15:01 | Holding(s) in Company |
| 28 Jul 2026 |
| Oxford BioDynamics shares surge after landing first paying customer for Orion genomics platform |
| 8 Oct 2025 | AIM movers: WH Ireland could lose general meeting vote and Angle refines strategy |
| 4 Sept 2025 | AIM movers: Potential extended use for Shield Therapeutics’ ACCRUFeR iron deficiency treatment and ex-dividends |
| 17 Jul 2026 | 09:15:01 | Holding(s) in Company |
| 28 Jul 2026 |
| Oxford BioDynamics shares surge after landing first paying customer for Orion genomics platform |
| 8 Oct 2025 | AIM movers: WH Ireland could lose general meeting vote and Angle refines strategy |
| 4 Sept 2025 | AIM movers: Potential extended use for Shield Therapeutics’ ACCRUFeR iron deficiency treatment and ex-dividends |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £13m | +0.4% | |
| £12m | +2.4% | |
| £12m | +0.5% | |
| £7m | -0.4% | |
OBDOxford Biodynamics PLC | £3m | -0.7% |
| £3m | -1.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £13m | +0.4% | |
| £12m | +2.4% | |
| £12m | +0.5% | |
| £7m | -0.4% | |
OBDOxford Biodynamics PLC | £3m | -0.7% |
| £3m | -1.0% |
